Edwards Lifesciences announced positive results from two real-world studies evaluating its Sapien transcatheter aortic valve replacement (TAVR) system. Results came from the TVT Registry data and continued to demonstrate strong outcomes. Edwards presented the data at Cardiovascular Research Technologies (CRT) 2024. A study of the latest TAVR technology, the Sapien 3 Ultra Resilia valve found […]
Edwards Lifesciences
TAVR, Critical Care drive Edwards to Q4 sales beat
Edwards Lifesciences shares dipped slightly today on fourth-quarter results that topped the consensus sales forecast. Shares of EW fell 0.2% to $88.11 in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — fell 0.3%. The Irvine, California-based company posted profits of $369.9 million. That equals […]
Edwards wins FDA approval for its Evoque replacement tricuspid valve
Edwards Lifesciences announced today that the FDA granted approval for its Evoque tricuspid valve replacement system. The company says this makes Evoque the first transcatheter therapy to receive an FDA nod to treat tricuspid regurgitation (TR). Irvine, California-based Edwards won CE mark for the Evoque system in October 2023. That approval also marked a first […]
Edwards plans to spin off critical care business next year
Edwards Lifesciences announced today that it intends to spin off its critical care business by the end of 2024. The company shared a number of key plans going forward as it outlined its plans for future growth. Among its plans, Edwards expects to spin off the critical care unit and its full range of smart […]
The biggest cardiovascular stories from TCT 2023
Every year, some of the biggest names in cardiovascular technologies come together in one place for TCT. This year’s 35th edition of the Transcatheter Cardiovascular Therapeutics annual scientific symposium was no different in San Francisco. Usual suspects like Medtronic and Abbott released data covering a range of products, while other big names like Edwards, GE […]
Edwards wins CE mark for Mitris Resilia valve
Edwards Lifesciences announced today that it received CE mark approval for its Mitris Resilia tissue valve replacement. News of the latest regulatory milestone follows the receipt of CE mark approval for the Evoque valve system last week. Edwards also reported positive TAVR data at TCT 2023 and recorded third-quarter sales growth in its latest earnings […]
Edwards Lifesciences says TAVR drove 12% sales growth in Q3
Edwards Lifesciences reported third-quarter results that met Wall Street expectations, with solid sales growth keeping it on track to boost revenue by up to 13% this year. Investors may have expected more from the maker of catheter-delivered heart implants, including transcatheter aortic valve replacement systems and transcatheter mitral and tricuspid therapies. The morning after the […]
5-year data supports Edwards Lifesciences’ Sapien 3 TAVR
Edwards Lifesciences announced new data demonstrating continued positive outcomes with its Sapien 3 transcatheter aortic valve replacement (TAVR). Results from the PARTNER 3 trial showed continued low rates of all-cause mortality, disabling stroke and rehospitalization at five years. Edwards presented the data at the 35th Transcatheter Cardiovascular Therapeutics (TCT) in San Francisco. It simultaneously published […]
Edwards wins CE mark for Evoque tricuspid valve replacement
Edwards Lifesciences announced today that it received CE mark for its Evoque tricuspid valve replacement system. Irvine, California-based Edwards says the regulatory nod makes it the first transcatheter valve replacement therapy to receive approval to treat tricuspid regurgitation (TR). Evoque features a nitinol self-expanding frame and an intra-annular sealing skirt. It makes the device’s tissue […]
Report: Patent practices triggered EU antitrust probe into Edwards
Reuters reports that European officials probed Edwards Lifesciences over potential antitrust activity because of patent practices. The outlet cites a person familiar with the matter regarding the European Commission’s scrutiny of the U.S.-based medtech company. Last month, the European Commission said it conducted a surprise inspection at an undisclosed medtech company. It listed that company […]
State of the industry — Execs ‘more bullish than ever’ on medtech
Ernst & Young’s 2023 Pulse of the Industry medical technology report may not have been overly positive, but medtech executives certainly are. The EY report highlighted sluggish revenues and post-COVID-19 corrections leading to a growth decline. In fact, it was the lowest growth in medtech since 2015. Roughly half of medtech stock price gains realized […]